A registry-based non-interventional post-authorization safety study to evaluate the long-term safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis using the PEDISTAD registry: a cohort design

ENCePP Code of conduct

Yes

Data sources

• Data source(s), other:
  Pedistad AD Disease Registry
• Data sources (types):
  Disease registry

  Non-interventional study

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Yes
• Check completeness:
  Yes
• Check stability:
  Unknown
• Check logical consistency:
  Yes

Data characterisation

• Data characterisation conducted:
  Unknown